Phosphodiesterase 9 (PDE9) Inhibitor
IMR-687 for Sickle Cell Disease
This trial is testing IMR-687, a medication, in adult patients with Sickle Cell Anemia who were in a previous study. It aims to see if the medication is safe and well-tolerated by monitoring side effects and body responses.
Histone Deacetylase Inhibitor
Panobinostat for Sickle Cell Disease
This trial is testing a drug called panobinostat to see if it is safe and effective in treating adults with sickle cell disease. Panobinostat is a pan histone deacetylase (HDAC) inhibitor, which has been shown to increase hemoglobin F induction and inhibit cell-specific inflammation.
Cell Therapy
Bone Marrow Transplant for Sickle Cell Disease
This trial uses stem cells from mismatched donors with certain immune cells removed to treat patients with severe blood disorders who lack a perfect donor match. The approach aims to replace damaged cells, reduce complications, and support recovery with additional immune cells. A new technique has been developed to improve the treatment process.
Popular Filters
Trials for Sickle Cell Disease Patients
Behavioral Intervention
Gerofit Exercise for Sickle Cell Disease
This trial is testing a personalized exercise program for adults aged 40 and older with sickle cell disease. The goal is to see if this exercise plan can improve their physical health and quality of life. Participants will be monitored regularly to track their progress and provide feedback on the program. Exercise programs have been studied as a potential therapeutic strategy for patients with sickle cell disease, showing benefits in functional capacity and cardiovascular health.
Small Molecule
Etavopivat for Sickle Cell Disease
This trial is testing a new oral medicine called etavopivat in patients with sickle cell disease or thalassemia. The medicine helps red blood cells produce energy more efficiently. The goal is to reduce the need for blood transfusions and increase hemoglobin levels.
Carbon Dioxide for Sickle Cell Anemia
This trial is looking at how blood flow and metabolism affects brain development in early life. SCA participants and healthy controls will have their blood flow and metabolism examined using MRI, and will also undergo cognitive assessments and brief questionnaires.
Trials for SCD Patients
Behavioral Intervention
Gerofit Exercise for Sickle Cell Disease
This trial is testing a personalized exercise program for adults aged 40 and older with sickle cell disease. The goal is to see if this exercise plan can improve their physical health and quality of life. Participants will be monitored regularly to track their progress and provide feedback on the program. Exercise programs have been studied as a potential therapeutic strategy for patients with sickle cell disease, showing benefits in functional capacity and cardiovascular health.
Small Molecule
Etavopivat for Sickle Cell Disease
This trial is testing a new oral medicine called etavopivat in patients with sickle cell disease or thalassemia. The medicine helps red blood cells produce energy more efficiently. The goal is to reduce the need for blood transfusions and increase hemoglobin levels.
Carbon Dioxide for Sickle Cell Anemia
This trial is looking at how blood flow and metabolism affects brain development in early life. SCA participants and healthy controls will have their blood flow and metabolism examined using MRI, and will also undergo cognitive assessments and brief questionnaires.
Trials With No Placebo
Behavioral Intervention
Gerofit Exercise for Sickle Cell Disease
This trial is testing a personalized exercise program for adults aged 40 and older with sickle cell disease. The goal is to see if this exercise plan can improve their physical health and quality of life. Participants will be monitored regularly to track their progress and provide feedback on the program. Exercise programs have been studied as a potential therapeutic strategy for patients with sickle cell disease, showing benefits in functional capacity and cardiovascular health.
Small Molecule
Etavopivat for Sickle Cell Disease
This trial is testing a new oral medicine called etavopivat in patients with sickle cell disease or thalassemia. The medicine helps red blood cells produce energy more efficiently. The goal is to reduce the need for blood transfusions and increase hemoglobin levels.
Carbon Dioxide for Sickle Cell Anemia
This trial is looking at how blood flow and metabolism affects brain development in early life. SCA participants and healthy controls will have their blood flow and metabolism examined using MRI, and will also undergo cognitive assessments and brief questionnaires.
Behavioural Intervention
Exercise for Sickle Cell Trait
This trial looks at how exercise affects people with sickle cell trait. It measures changes in the body before and after exercise to see how different biomarkers are affected. This could help explain why some people with sickle cell trait have complications after strenuous exercise.
Frequently Asked Questions
Introduction to sickle cell anemia
What are the top hospitals conducting sickle cell anemia research?
In the ongoing battle against sickle cell anemia, several top hospitals are making significant strides in clinical trials. Cincinnati Children's Hospital Medical Center in Cincinnati has taken a proactive approach with three active trials dedicated to this condition. Although they have just one completed trial on record since their first investigation in 2011, their commitment to advancing sickle cell anemia research is commendable. The National Institutes of Health Clinical Center, located in Bethesda, is another major player with two ongoing trials and a total of three completed studies since initiating their first trial back in 2001.
Duke University in Durham recently joined the efforts by conducting one active clinical trial for sickle cell anemia. While they do not yet have any completed trials under their belt, their involvement marks a promising step towards understanding and treating this complex disease. Meanwhile, at the University of Florida in Gainesville, researchers are focusing on one active sickle cell anemia trial and have already achieved considerable progress with one previously conducted study dating back to 2022.
Last but not least is the Innovative Clinical Research Institute (ICRI) located in Whittier. Despite being relatively new to exploring sickle cell anemia through clinical trials, ICRI has shown dedication by currently conducting one active trial focused on this condition.
These hospitals exemplify the collective determination within the medical community to find effective treatments for individuals living with sickle cell anemia—a genetic disorder that affects red blood cells' shape and function leading to complications like chronic pain episodes known as crises or organ damage due insufficient oxygen supply.Trial data from these institutions will contribute immensely toward scientific breakthroughs aimed at improving patients' quality of life while fostering hope for better treatment options and ultimately finding a cure
Which are the best cities for sickle cell anemia clinical trials?
When it comes to sickle cell anemia clinical trials, several cities emerge as leading locations for research. Pittsburgh, Pennsylvania takes the lead with 6 active trials focusing on treatments like MitoQ and CD3/CD19 depleted leukocytes. Cincinnati, Ohio follows closely behind with 4 ongoing studies investigating Etavopivat tablets, ARU-1801, and Imatinib Mesylate. Atlanta, Georgia and Indianapolis, Indiana tie with 3 active trials each exploring treatments such as Voxelotor and Hydroxyurea. Lastly, Durham, North carolina hosts 2 active trials examining interventions like exercise and Etavopivat tablets. These cities offer individuals affected by sickle cell anemia opportunities to participate in groundbreaking clinical research that may drive advancements in care for this condition.
Which are the top treatments for sickle cell anemia being explored in clinical trials?
[Sickle cell anemia](https://www.withpower.com/clinical-trials/sickle-cell-anemia) research is making strides in the search for effective treatments. Currently, two top contenders are being explored in clinical trials: exercise and CHOICES. Exercise has shown promise with two active trials dedicated to sickle cell anemia since its first listing in 2021. Similarly, CHOICES, a newer player on the scene, is also being investigated with one ongoing trial focused specifically on sickle cell anemia since its introduction in 2022. These innovative approaches hold potential for improving outcomes and quality of life for individuals affected by this challenging condition.
What are the most recent clinical trials for sickle cell anemia?
Recent clinical trials offer hope for individuals living with sickle cell anemia, as researchers continue to explore innovative treatment options. One such trial is CTX001, a Phase 3 study that investigates its effectiveness in managing sickle cell anemia. Additionally, briquilimab has shown promise in stem cell transplant recipients with SCD in both Phase 1 and Phase 2 trials. Another exciting development is the investigation of voxelotor's potential benefits for sickle cell anemia patients through Phase 2 studies. Etavopivat tablets have also undergone evaluation during their Phase 2 trial phase. Continued research into these treatments brings optimism for improved outcomes and quality of life for those affected by sickle cell anemia.
What sickle cell anemia clinical trials were recently completed?
Recently, several clinical trials investigating potential treatments for sickle cell anemia have reached significant milestones. These trials hold promise for improving the management and outcome of this challenging condition. Notably, a trial sponsored by Global Blood Therapeutics was completed in July 2021 to evaluate the safety and efficacy of their investigational drug voxelotor. In addition, a Phase 2 trial conducted by Novartis investigating crizanlizumab's ability to reduce vaso-occlusive crises in patients with sickle cell disease was concluded in December 2020. The completion of these important studies marks crucial progress toward finding better therapies for individuals affected by sickle cell anemia.